Stock·LSE·£
Adicet Bio, Inc., a pioneering biotechnology firm, is dedicated to the discovery and development of "off-the-shelf" gamma delta T cell therapies aimed at combating cancer and other illnesses. Their innovative approach involves genetically modifying gamma delta T cells by integrating both chimeric antigen receptors (CARs) and T-cell receptor-mimicking antibodies. This proprietary engineering is designed to achieve highly selective tumor targeting, bolster both innate and adaptive anti-tumor immune responses, and enhance cell persistence for durable therapeutic outcomes in patients. Their lead therapeutic candidate, ADI-001, is currently progressing through Phase I clinical trials as a potential treatment for non-Hodgkin's lymphoma. Furthermore, their pipeline includes ADI-002, currently undergoing preclinical studies for various solid tumors. The company operates out of Boston, Massachusetts.
See 0HX7.L price live on your physical desk display. Set alerts with iOS & Android apps.
